The legal fight over Kadima Neuropsychiatry Institute tests NRx Pharmaceuticals’ acquisition discipline, financing credibility and evolving interventional psychiatry strategy.
Read how AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 case in ALS and what its Phase 3 trial must prove.
Discover how Otsuka’s centanafadine Phase 3b ADHD data could shape FDA review and the nonstimulant treatment market. Read more.
Read how Agenus’ three-year BOT+BAL survival update could reshape expectations in refractory MSS metastatic colorectal cancer.
See why Star Therapeutics’ complete VGA039 data at ISTH 2026 could reshape von Willebrand disease prophylaxis and Incyte’s strategy.
Read how Epicrispr’s early EPI-321 muscle gains could reshape FSHD drug development, and what the small trial still cannot prove.
Omeros faces a CHMP refusal for narsoplimab in TA-TMA. Read what the EU re-examination means for evidence, access and launch plans.
Read how Shionogi’s NeuroBANK partnership could shape Radicava evidence, ALS trial design and real-world treatment research.
The positive opinion moves ruxolitinib cream closer to a broader European label for adults inadequately controlled by standard topical therapies, opening a potential treatment position between conventional creams and systemic medicines.
Discover how Datroway’s EU recommendation could reshape first-line treatment for metastatic triple-negative breast cancer. Read the analysis.